Sign in to view content

Faricimab Causes Rapid and Sustained Intraocular Suppression of Ang-2 and VEGF-A for Up to 16 Weeks in nAMD and DME

Rajeev H. Muni, MD, MSC, FRCS(C), FASRS

Video
Published 2023

Related

Pharmacokinetic Profile of the Port Delivery System With Ranibizumab in the Phase 3 Archway Trial
John W. Kitchens, MD
Annual Meeting Talks
2021
Clinical Evaluation and PK/PD Modeling of the DARPin Therapeutic Abicipar for the Treatment of Neovascular Age‐Related Macular Degeneration
Peter K. Kaiser, MD FASRS
Annual Meeting Talks
2020
Pharmacokinetic Profile of the Port Delivery System With Ranibizumab: From PRN Refills in Phase 2 Ladder to Fixed 24-Week Refills In Phase 3 Archway
Dilsher S. Dhoot, MD
Annual Meeting Talks
2020

Category: Diabetic Retinopathy

See more